Pacific Edge Limited (ASX:PEB)

Market Cap	256.53M +97.8%
Revenue (ttm)	10.83M -42.8%
Net Income	-29.79M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,530
Open	0.2100
Previous Close	0.2050
Day's Range	0.2050 - 0.2100
52-Week Range	0.1200 - 0.2650
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 19, 2026

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the stratification and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up in microhematuria patients; Cxbladder Detect, which improve practice workflow and efficiency in urologi...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PEB

Financial Performance

In fiscal year 2026, Pacific Edge's revenue was 13.01 million, a decrease of -42.80% compared to the previous year's 22.75 million. Losses were -35.78 million, 19.5% more than in 2025.

Financial numbers in NZD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error